Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT

• Yishan Ye,
• Myriam Labopin,
• Jia Chen,
• Depei Wu,
• Tobias Gedde-Dahl,
• Didier Blaise,
• Gérard Socie,
• Edouard Forcade,
• Urpu Salmenniemi,
• Sébastien Maury,
• Jurjen Versluis,
• Ali Bazarbachi,
• Arnon Nagler,
• Eolia Brissot,
• Lin Li,
• Yi Luo,
• Jimin Shi,
• Fabio Ciceri,
• He Huang,
• Mohamad Mohty,
• Norbert Claude Gorin

Affiliations

Yishan Ye

The First Affiliated Hospital, Zhejiang University School of Medicine

Myriam Labopin

EBMT Paris Office

Jia Chen

First Affiliated Hospital of Soochow University

Depei Wu

First Affiliated Hospital of Soochow University

Tobias Gedde-Dahl

Oslo University Hospital, Rikshospitalet

Didier Blaise

Program of Transplant and cellular immunotherapy, Department of Hematology, Institut Paoli Calmettes, Management Sport Cancer (MSC) Lab, Aix Marseille University (AMU)

Gérard Socie

Saint-Louis Hospital, BMT Unit

Edouard Forcade

CHU Bordeaux, Hopital Haut-Leveque

Urpu Salmenniemi

HUCH Comprehensive Cancer Center

Sébastien Maury

Hôpital Henri Mondor

Jurjen Versluis

Erasmus MC Cancer Institute

Ali Bazarbachi

Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center

Arnon Nagler

Department of Bone Marrow Transplantation, Chaim Sheba Medical Center

Eolia Brissot

EBMT Paris Office

Lin Li

The First Affiliated Hospital, Zhejiang University School of Medicine

Yi Luo

The First Affiliated Hospital, Zhejiang University School of Medicine

Jimin Shi

The First Affiliated Hospital, Zhejiang University School of Medicine

Fabio Ciceri

Ospedale San Raffaele s.r.l., Haematology and BMT

He Huang

The First Affiliated Hospital, Zhejiang University School of Medicine

Mohamad Mohty

EBMT Paris Office

Norbert Claude Gorin

EBMT Paris Office